Chardan Capital Reiterates Buy Rating for Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals (NASDAQ:RVPH)‘s stock had its “buy” rating reissued by research analysts at Chardan Capital in a note issued to investors on Monday,Benzinga reports. They presently have a $2.00 price target on the stock.

A number of other analysts have also commented on the stock. Benchmark cut their price objective on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating on the stock in a research report on Monday, September 15th. HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Reviva Pharmaceuticals in a research note on Tuesday, December 23rd. Wall Street Zen upgraded shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Wednesday, October 8th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $2.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $3.86.

Reviva Pharmaceuticals Price Performance

RVPH stock opened at $0.32 on Monday. The stock has a market capitalization of $37.18 million, a P/E ratio of -0.70 and a beta of 0.08. Reviva Pharmaceuticals has a fifty-two week low of $0.25 and a fifty-two week high of $2.17. The business has a 50-day moving average of $0.51 and a 200-day moving average of $0.49.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05. Equities analysts expect that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Institutional Trading of Reviva Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of RVPH. XTX Topco Ltd acquired a new stake in shares of Reviva Pharmaceuticals in the second quarter valued at approximately $31,000. Lido Advisors LLC bought a new stake in Reviva Pharmaceuticals in the 3rd quarter valued at $37,000. NewEdge Advisors LLC acquired a new stake in Reviva Pharmaceuticals during the 1st quarter valued at $58,000. Geode Capital Management LLC increased its holdings in shares of Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after purchasing an additional 29,063 shares during the last quarter. Finally, Persistent Asset Partners Ltd increased its holdings in shares of Reviva Pharmaceuticals by 300.0% in the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock valued at $244,000 after purchasing an additional 480,864 shares during the last quarter. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.